Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other financing activities (2018 - 2025)

Heron Therapeutics' Other financing activities history spans 8 years, with the latest figure at -$1.4 million for Q4 2025.

  • For Q4 2025, Other financing activities fell 3415.38% year-over-year to -$1.4 million; the TTM value through Dec 2025 reached -$1.2 million, down 484.16%, while the annual FY2025 figure was $160000.0, 47.19% down from the prior year.
  • Other financing activities reached -$1.4 million in Q4 2025 per HRTX's latest filing, down from -$51000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $4.2 million in Q2 2021 to a low of -$1.4 million in Q4 2025.
  • Average Other financing activities over 5 years is $81600.0, with a median of -$51500.0 recorded in 2021.
  • The largest YoY upside for Other financing activities was 481.82% in 2025 against a maximum downside of 3415.38% in 2025.
  • A 5-year view of Other financing activities shows it stood at -$123000.0 in 2021, then plummeted by 74.8% to -$215000.0 in 2022, then skyrocketed by 99.07% to -$2000.0 in 2023, then plummeted by 1850.0% to -$39000.0 in 2024, then crashed by 3415.38% to -$1.4 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Other financing activities are -$1.4 million (Q4 2025), -$51000.0 (Q3 2025), and $194000.0 (Q2 2025).